BCR-ABL1 tyrosine kinase inhibitors have dramatically improved outcomes for patients with chronic myeloid leukemia, and current studies are investigating whether some patients may be able to suspend therapy yet maintain response in a state known as "treatment-free remission" (TFR). Results from ongoing studies suggest that z 40% to 60% of patients in sustained (generally 2 years) deep molecular response (defined as a 4-log or deeper reduction in BCR-ABL1 transcripts, depending on the study) who attempt TFR may successfully remain off treatment. Results from TFR clinical trials, patient considerations for attempting TFR, and potential predictive factors associated with successful TFR are reviewed herein.
Introduction
The management of Philadelphia chromosomeepositive chronic myeloid leukemia (CML) has undergone remarkable advancement over the past 15 years with the availability of 5 BCR-ABL1 tyrosine kinase inhibitors (TKIs; imatinib, nilotinib, dasatinib, bosutinib, and ponatinib), in addition to the non-TKI therapies omacetaxine mepesuccinate and pegylated interferon (IFN) alfa.
1,2 Imatinib, nilotinib, and dasatinib are indicated for frontline treatment of patients with CML in chronic phase (CML-CP) 1, 2 ; with these options, z 70% to 80% of patients in clinical trials achieved complete cytogenetic responses by 12 months, 1 and > 90% can expect to survive > 5 years beyond diagnosis. 3, 4 Response to TKI therapy is assessed by hematologic, cytogenetic, and molecular testing and is benchmarked against time-based milestones to guide treatment decisions. 1 conventional RQ-PCR. Patients are more likely to achieve, and to achieve more rapidly, each milestone with second-generation TKIs than with imatinib, but the clinical benefit of achieving more rapid responses is undetermined. 3, 4 With multiple potent therapies available, more patients may be able to achieve sustained deep MR (MR 4 or better). 6 This has led to the natural hypothesis that some patients, with time, might be able to safely discontinue TKIs and remain in treatment-free remission (TFR). 7 Successful TFR may represent a "functional cure," in which the risk of clinical relapse is low or absent, although BCR-ABL1 transcripts may be detectable. To date, the majority of evidence regarding TFR is based on patients who received long-term therapy with imatinib [8] [9] [10] [11] [12] [13] [14] [15] ; however, TFR is also being investigated in patients treated with nilotinib and dasatinib. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 300 mg twice daily achieved MR 4.5 by 6 years compared with 33%
of patients treated with imatinib 400 mg once daily. 27 In the Dasatinib Versus Imatinib Study in Treatment-Naive CML Patients (DASISION), more patients achieved MR 4.5 by 5 years with dasatinib 100 mg once daily (42%) than with imatinib 400 mg once daily (33%). 4 Deep MR has been associated with increased long-term survival rates 28 ; however, survival rates are high with all frontline TKIs, and no survival advantage has been observed with nilotinib or dasatinib compared with imatinib at the approved doses. 4, 27 Dose optimization of frontline imatinib, or switching from imatinib to a second-generation TKI, may also improve deep MR rates compared with standard-dose imatinib. In CML-Study IV, higher rates of MR 4.5 by 6 years were observed with high-dose imatinib (800 mg/day; 66%) than with standard-dose imatinib (400 mg/day; 56%). 28 The Therapeutic Intensification in 
Studies Investigating TFR
Several studies have investigated TFR following long-term imatinib therapy. [8] [9] [10] [11] [12] [13] [14] [15] Among the first large TFR studies were Stop Imatinib (STIM1) and TWISTER, which enrolled patients with 3 years of prior imatinib therapy and 2 years of sustained undetectable BCR-ABL1 (confirmed in a central laboratory with sensitivity to > 5-log [STIM1] or 4.5-log [TWISTER] reductions in BCR-ABL1). 7, 12 In both studies, patients with detectable BCR-ABL1 transcripts confirmed in a second test (or loss of MMR in a single assessment) were considered to have molecular relapse, triggering retreatment. Approximately 40% of patients in each study were able to maintain TFR for > 3 years, and the majority of molecular relapses occurred during the first 6 months after imatinib was suspended. 7, 9, 12 Subsequent investigations "moved the bar" by documenting that undetectable BCR-ABL1 is not required for successful TFR. 11, 15 The According to STIM (A-STIM) trial enrolled patients with 3 years of imatinib treatment and 2 years of either undetectable BCR-ABL1 ( 40,000 ABL1 copies) or occasional positive transcripts (BCR-ABL1 IS < 0.1%). 11 Of great significance was the fact that the authors found no difference in the 12-month molecular relapse rate between patients with stable undetectable BCR-ABL1 and those with occasional positivity. An important distinction of and paradigm shift initiated by A-STIM relative to earlier TFR trials is that, in A-STIM, molecular relapse was redefined as loss of MMR rather than re-emergence of BCR-ABL1. By 2 years, the cumulative rate of molecular relapse was 36%, whereas the cumulative rate of loss of undetectable BCR-ABL1 (molecular relapse as defined in STIM1) was 54%. The A-STIM study suggested that loss of MMR could be a safe and pragmatic definition of molecular relapse. Of the 31 patients in A-STIM who reinitiated treatment after loss of MMR, all regained MMR, and 23 regained undetectable BCR-ABL1 with 17 months' median retreatment. In the more recent European Stop Tyrosine Kinase Inhibitor (EURO-SKI) trial, patients with 3 years of TKI treatment and MR 4 sustained for 1 year were eligible. 15 Of 717 evaluable patients in EURO-SKI (with a median follow-up of 10 months), the rate of molecular relapseefree survival (no loss of MMR) was 62% at 6 months and 56% at 12 months. Discontinuation studies with nilotinib and dasatinib, which aim to capitalize on the higher rates of MR compared with imatinib, 4, 27 are ongoing. Results from some of these studies have been reported (Table 2) . 15 ).
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In the Dasatinib Discontinuation (DADI) study, patients with CML-CP who received dasatinib following resistance to or intolerance of imatinib and had BCR-ABL1 IS < 0.0069% for 1 year 
Considerations for Cessation of TKI Therapy

Patient Preferences in TFR
Patients' levels of understanding of the risks and benefits of TFR have been queried in surveys. [42] [43] [44] [45] [46] A significant proportion of patients (42%-71%) have expressed a cautious willingness to attempt TFR. [42] [43] [44] [45] However, in a survey of 1133 Italian patients, 49%
indicated they would not interrupt treatment if they achieved a "perfect and long-lasting response" owing to fear of relapse. 42 In another survey, patients' willingness to stop TKI therapy was found to be inversely related to the expected risk of relapse 45 ; safety concerns surrounding TFR have been repeatedly identified in other surveys. 43, 44 Motivators for attempting TFR may include relief from toxicities, quality-of-life improvements, or economic considerations. 43, 44, 46 Unfortunately, many patients who experience chronic toxicities may be unable to achieve the deep MR needed to qualify for TFR studies 47, 48 ; however, the potential to minimize the ongoing risk of developing new toxicities during long-term TKI therapy, including cardiovascular events or other serious AEs, is a potential benefit of TFR. Although quality-of-life improvements (such as lessening of fatigue) have been observed following TKI withdrawal, 49 the effect on toxicities may not be unidirectional; new or worsening AEs (including musculoskeletal pain, pruritus, and/or exacerbation of preexisting inflammatory diseases) have also been reported following TKI cessation, although these may be temporary. 13, 19, [50] [51] [52] Although surveyed patients noted financial considerations related to TFR, [43] [44] [45] 53 little information is available on the financial impact of TFR. An analysis from STIM1 estimated a total savings of V5.5 million for the 100 patients attempting TFR. 54 A single-institution retrospective analysis of 29 patients who discontinued therapy estimated a net savings of > $3 million, largely from decreased medication costs, despite increased costs associated with intensified molecular monitoring. 55 Similarly, a Brazilian report noted substantial projected healthcare savings resulting from TFR. 56 Owing to the more rapid achievement of deep MR with second-generation TKIs, 3,4 the potential economic impact of TFR may be greater for patients treated with nilotinib or dasatinib than with imatinib. Conversely, the availability of generic imatinib may lessen therapy costs and, in turn, affect any cost-value assessment of secondgeneration TKIs in the frontline setting.
Monitoring
Frequent, highly sensitive molecular monitoring of BCR-ABL1 levels is key for ensuring the safety of patients attempting TFR, particularly during the first year of TFR, and during retreatment if needed. 26 The majority of molecular relapses have been observed within 6 months of TKI cessation, [9] [10] [11] [12] 16, 17 and nearly all patients regained MR with retreatment. 7, 9, 11, 12, 54 14 A concern for patients considering treatment cessation is the risk of relapse and a fear that their CML may not remain responsive to therapy following relapse. However, across all TFR studies to date, > 450 patients have reinitiated treatment following molecular relapse during a treatment-free period; among these patients, only a single case of progression and only 2 reports of patients who did not regain MMR after restarting therapy have been reported. In TFR studies that assessed deep molecular responses after treatment was restarted because of molecular relapse, only 28 patients did not regain a deep response as defined in the study (as of the latest report from each study). 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [22] [23] [24] 34, 35, [39] [40] [41] 57, 58 The potential risks of not regaining a molecular response or progressing to advanced disease will continue to be clarified as data from additional studies accumulate.
Predictors of Successful TFR
A variety of factors have been identified as potentially predictive of successful TFR. 9, 12, 13, [15] [16] [17] 49, [59] [60] [61] In STIM1, patients with low/ intermediate Sokal risk and those with a longer duration of imatinib therapy were more likely to maintain TFR. 9 Similarly in EURO-SKI, treatment and MR 4 durations were predictive of TFR success. 15 In the Korean Imatinib Discontinuation (KID) study, which required > 3 years of imatinib treatment and undetectable BCR-ABL1 for 2 years, longer ( 62 months) duration of TKI therapy and development of an imatinib withdrawal syndrome (including musculoskeletal pain and/or pruritus), 13 as well as prior allogeneic hematopoietic stem cell transplant, 59 were favorable for TFR. In the ISAV study, younger age and detectable BCR-ABL1 by digital PCR at study entry were both unfavorable: no patient aged < 45 years with baseline digital PCR positivity remained in TFR by 24 months. 49 In DADI, no association was found between duration of prior TKI therapy and successful TFR, although higher rates of TFR at 12 months were observed in patients who demonstrated (by immune profiling) an increased number of natural killer (NK) cells in the peripheral blood during the consolidation phase prior to discontinuation. 17 Shortening of telomere length has also been associated with higher rates of successful TFR and may be a predictor for response. 61 
Treatment-Free Remission in CML
Trends for higher rates of successful TFR among patients with prior IFN therapy have been repeatedly noted, 7, 12, 60 although this trend could be partially owing to a selection bias for long treatment duration and low biological risk among patients with prior IFN. 26 In a retrospective analysis from Japan, patients who remained in TFR at 12 months after suspending treatment were significantly more likely to have received prior IFN (20 of 26 patients remaining in TFR at 12 months had prior IFN) than those who relapsed by 12 months (5 of 14 patients had prior IFN; P ¼ .0102). 60 In TWISTER, patients who received IFN therapy prior to imatinib had an estimated 3-year TFR rate of 52% compared with 34% in patients without prior IFN (P > .05).
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In patients with CML, IFN impacts CML and other cells through multiple pathways, although the most crucial mechanisms of IFN therapy are poorly understood. 62 IFN has been shown to promote the activation of immune effector cells in patients with CML. 62 Thus, a role for the immune system, and in particular, NK cell number, phenotype, and activation status, has been suggested in maintaining deep MR and TFR. 17, [63] [64] [65] A significant association between NK cell killer-cell immunoglobulin-like receptor haplotype A homozygosity and improved likelihood of successfully maintaining TFR has been reported. 66 Markers of active immunosurveillance may be useful for identifying patients with a higher or lower likelihood of achieving TFR. 65 TFR following treatment with nilotinib and IFN is being investigated ( Table 2 ).
Other factors have been cited as cautionary for selection of appropriate TFR candidates. Intuitively, patients with atypical BCR-ABL1 transcripts not easily measured with RQ-PCR may be difficult to monitor effectively while off TKI therapy. Additionally, there is limited experience with discontinuation among patients with BCR-ABL1 mutations or a history of TKI resistance or advanced CML. Additionally, TKI discontinuation in pediatric CML has not been fully explored. 26 
Conclusions and Future Directions
Approximately 40% to 60% of patients with CML-CP who achieve sustained ( 2 years) deep MR with TKI therapy can achieve TFR. Molecular relapses typically occurred within 6 months, and patients quickly regained their prior depth of MR upon retreatment with the same TKI. 26 As such, many TFR trials require monthly RQ-PCR monitoring for the first 6 to 12 months, with a gradual reduction in frequency thereafter. 7, 11, 12, 16 Clinical progression of CML related to participation in a TFR study has been observed only once, 11 although fear of progression could limit patient participation in trials.
As data from TFR studies continue to mature, questions remain about longer-term outcomes as well as the proper selection and molecular monitoring of patients. Novel treatment approaches that may enable more patients to achieve TFR include TKI dose optimization, treatment combinations or sequencing, and incorporation of immunotherapy agents. 62, 67, 68 One area of research ripe for future development would be strategies to permit subsequent TFR attempts after failure of the first attempt. 26, 69 Although it is debatable whether available data are sufficient to support TFR in routine clinical practice, United States guidelines have recently incorporated ground rules for this endeavor. 2, 26 Currently, the decision to pursue TFR is complex and highly individualized. It is not considered a safe approach for patients with CML with a history of accelerated phase or blast crisis, and controversy exists regarding attempting TFR in patients with a history of resistance to therapy within chronic phase. 26 Patients may be more likely to consider TFR because of extenuating health circumstances; desire for TFR also has overlap with desire to achieve pregnancy, although these circumstances are strikingly different, as reinitiation of TKI therapy in the case of relapse may not be immediately addressable during active pregnancy. 1,2,13,53,60 Potential economic benefits and reduction of treatment complications (including cardiovascular events or pleural effusions 3, 4, 32, 33 ) will require long-term comparisons between continuous/lifelong TKI use and finite TKI treatment and subsequent TFR. Irrespective of whether TFR is ready for routine use in clinical practice, it has become a natural extension of our approach to definitive treatment of patients with CML-CP and is a promising next chapter in the progress for patients with CML.
